Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 11, 2010, Pages 1454-1460

  Milán Segovia, Rosa Del Carmen ^a,b   Dominguez Ramirez A M ^a   Jung Cook, H ^c   Magana Aquino M ^d   Romero Mendez M C ^b   Medellin Garibay S E ^b   Vigna Perez M ^b   Romano Moreno, S ^b  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

Author keywords

Fixed dose combinations; Relative bioavailability; Rifampicin

Indexed keywords

GENERIC DRUG; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFATER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; HEALTH CARE SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MEXICO; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUGS, GENERIC; HUMANS; ISONIAZID; MEXICO; PYRAZINAMIDE; RIFAMPIN; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 78049449334     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Secretaría de Salud, Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. Programas Preventivos. Alianza comunitaria SOLUCIÓN TB. Mexico City, Mexico: CENAVE, Boletín informativo 2010; 12, Febrero. http://www.cenave.gob.mx/tuberculosis/WEB/ descargas-1/2010/BTB-Feb.pdf Accessed July 2010. [Spanish]
2. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79: 61-68. (Pubitemid 32154097)
3. Peloquin C. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183. (Pubitemid 35252827)
4. van Crevel R, Alisjahbana B, de Lange W C, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002; 6: 497-502. (Pubitemid 34601866)
5. McIlleron H, Wash P, Burger A, Norman J, Folb P I, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-1177.
6. Agrawal S, Kaur K J, Singh I, Bhade S, Kaul C L, Panchagnula R. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations. Int J Tuberc Lung Dis 2005; 9: 1273-1280. (Pubitemid 41735609)
7. Singh S, Mariappan T T, Sanka R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FCD) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17. (Pubitemid 32905361)
8. Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 2004; 271: 1-4. (Pubitemid 38210078)
9. Panchagnula R, Parmar J, Kaur K, Singh I, Bade S R, Ashokraj Y. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations. Int J Pharm 2006; 313: 5-13.
10. Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 2005; 26: 321-334.
11. Becker C, Dressman J B, Junginger H E, et al. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci 2009; 98: 2252-2267.
12. Shishoo C J, Shah S A, Rathod I S, Savale S S, Kotecha J S, Shah P B. Stability of rifampicin in dissolution medium in presence of isoniazid. Int J Pharm 1999; 190: 109-123.
13. Immanuel C, Gurumurthy P, Ramachandran G, Venkatesan P, Chandrasekaran V, Prabhakar R. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. I ndian J Med Res 2003; 118: 109-114.
14. Pillai G, Fourie P B, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316.
15. World Health Organization. Annex 8: proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series No 937. Geneva, Switzerland: WHO, 2006. http://apps.who.int/prequal/info-general/ documents/TRS937/WHO-TRS-937-annex8-eng.pdf Accessed July 2010.
16. Farmacopea de los Estados Unidos de América. Edición anual en Español. USP 29/NF 24. Rockville, MD, USA: United States Pharmacopeial Convention, 2006: pp 2100-2101. [Spanish]
17. Le Guellec Ch, Gaudet M L, Lamanetre S, Breteau M. Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. Therapeutic Drug Monit 1997; 19: 669-674.
18. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-177-SSA1-1998. Mexico City, Me xico: Secretaría de Salud, 1999. [Spanish]
19. max/AUC is an effective metric in investigations of bioequivalence. Pharm Res 1995; 12: 937-942.
20. Padgaonkar K A, Revankar S N, Bhatt A D, et al. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. Int J Tuberc Lung Dis 1999; 3: 627-631.
21. Fourie B, Pillai G, McIlleron H, Panchagnula R, Ellard G. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administered in loose combination. Model protocol. Geneva, Switzerland: World Health Organization Communicable Diseases Cluster, 1999. http://whqlibdoc.who.int/hq/1999/WHO-CDS-TB-99.274.pdf Accessed July 2010.
22. Ashokraj Y, Singh I, Kaur K J, et al. Establishment of a reference formulation for bioequivalence assessment of rifampicincontaining FDCs: an essential step towards improving tuberculosis treatment. Int J Tuberc Lung Dis 2005; 9: 791-796.
23. Comisión Federal para la Protección contra Riesgos Sanitarios. Comisión de Autorización Sanitaria. Relación de medicamentos de referencia. Mexico City, Mexico: Comisión de Autorización Sanitaria, 2009. http://201.147.97.103/work/sites/cfp/ resources/LocalContent/1466/6/RelMedRefDic09.pdf Accessed July 2010. [Spanish]
24. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.
25. Ashokraj Y, Agrawal S, Varma M V, et al. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study. Int J Tuberc Lung Dis 2004; 8: 1081-1088.
26. Ellard G A, Fourie P B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S301-S308.
27. Agrawal S, Kaur K J, Singh I, Bhade S R, Kaul C L, Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2002; 233: 169-177. (Pubitemid 34230429)
28. McIlleron H, Gabriels G, Smith P J, Fourie P B, Ellard G A. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S329-S335.
29. Agrawal S, Kaur K J, Singh I, Bhade S R, Kaul C L, Panchagnula R. Determination of rifampicin bioequivalence in a threedrug FDC by WHO and Indian protocols: effect of sampling schedule and size. Int J Tuberc Lung Dis 2005; 9: 75-80.
30. Pargal A, Rani S. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis 2001; 5: 70-79.
31. Agrawal S, Singh I, Kaur K J, Bhade S, Kaul C L, Panchagnula R. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res 2004; 50: 317-327.
32. McIlleron H, Wash P, Burger A, Folb P, Smith P. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361. (Pubitemid 34263694)
33. Laserson K F, Kenyon A S, Kenyon T A, Layloff T, Binkin N J. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001; 5: 448-454.
34. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis. Drugs 2003; 63: 535-553.
35. Consejo de Salubridad General. Acuerdo por el que se adiciona y modifica la relación de especialidades farmacéuticas susceptibles de incorporarse al Catálogo de Medicamentos Genéricos. Diario Oficial de la Federación, 21 febrero 2008. http://cdivirtual.salud.gob.mx/ interiores/diario-oficial/diario-2008/pdfs/febrero/a210208.pdf Accessed July 2010. [Spanish]